about
Optimising inhaled mannitol for cystic fibrosis in an adult populationBarriers to inhaled gene therapy of obstructive lung diseases: A reviewCystic fibrosis remodels the regulation of purinergic signaling by NTPDase1 (CD39) and NTPDase3Lobectomy in patients with cystic fibrosis.A first-year dornase alfa treatment impact on clinical parameters of patients with cystic fibrosis: the Brazilian cystic fibrosis multicenter studySputum glucose and glycemic control in cystic fibrosis-related diabetes: a cross-sectional studyN-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles.Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data.Cigarette smoke and CFTR: implications in the pathogenesis of COPDThe development of bronchiectasis on chest computed tomography in children with cystic fibrosis: can pre-stages be identified?Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier.Management of pneumothorax in emergency medicine departments: multicenter trial.Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection.What matters in chronic Burkholderia cenocepacia infection in cystic fibrosis: Insights from comparative genomics.Pneumomediastinum as a presenting feature of allergic bronchopulmonary aspergillosis in a child with cystic fibrosis.Population Pharmacokinetics of Amikacin in Adult Patients with Cystic FibrosisPneumothorax in cystic fibrosis
P2860
Q26797457-FD3F6DBF-713F-42AD-8C40-0D8DB5C23710Q29248141-3356A679-1B3F-4DE5-8456-E6107AE6C994Q33916983-05B823D4-CFC2-4536-B016-C5137E3C0A11Q34238232-495C271C-A6FB-45C4-9777-C53545F6FC5CQ34279583-FEC8EF11-6455-40A1-8DF1-F1225D21BA3CQ35214383-B260E8A4-3487-47DA-AF26-CA1C0B422423Q35568532-EC9CA204-BB0E-4B96-80EB-F89F46702767Q36368310-AB7DBE3E-70DB-42CE-A070-FAC6E208718AQ37234904-3FCE09DF-180A-4D84-A6DD-057E49B7D376Q37402194-B81600F3-AD17-45E2-8EF6-9A5E332BE721Q37633436-1CB18138-B459-4D6C-9611-F3CEDE2F3AACQ37639503-550A5D9E-DABE-4158-BBC8-70713E0A42CFQ41907356-58D3F4D8-9CEC-4BB2-B8B2-0281F8091F21Q47684142-A59F7E7E-07D7-47A6-955A-5BEDF4D39607Q53156928-5A5ADCA6-9925-4208-BEC3-AAE3220BFB65Q57151052-5FEEF231-0B29-4A62-92D2-B483F2B75922Q57654550-DD70E5C7-5E1D-482E-9EAF-A0B0F3AD0EAF
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pulmonary complications of cystic fibrosis.
@en
Pulmonary complications of cystic fibrosis.
@nl
type
label
Pulmonary complications of cystic fibrosis.
@en
Pulmonary complications of cystic fibrosis.
@nl
prefLabel
Pulmonary complications of cystic fibrosis.
@en
Pulmonary complications of cystic fibrosis.
@nl
P1433
P1476
Pulmonary complications of cystic fibrosis.
@en
P2093
Patrick A Flume
P304
P577
2009-05-01T00:00:00Z